Literature DB >> 25489834

Who owns CRISPR-Cas9 in Europe?

András Kupecz1.   

Abstract

Recent developments in the prosecution of the CRISPR-Cas9 patent in Europe highlight the differences between the intellectual property regimes of Europe and the United States.

Mesh：

Year:  2014        PMID： 25489834     DOI： 10.1038/nbt.3086

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


  3 in total

1.  First CRISPR-Cas patent opens race to stake out intellectual property.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2014-07       Impact factor: 54.908

Review 2.  Development and applications of CRISPR-Cas9 for genome engineering.

Authors:  Patrick D Hsu; Eric S Lander; Feng Zhang
Journal:  Cell       Date:  2014-06-05       Impact factor: 41.582

3.  A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.

Authors:  Martin Jinek; Krzysztof Chylinski; Ines Fonfara; Michael Hauer; Jennifer A Doudna; Emmanuelle Charpentier
Journal:  Science       Date:  2012-06-28       Impact factor: 47.728
  3 in total
  2 in total

Review 1.  Genome editing: intellectual property and product development in plant biotechnology.

Authors:  Helga Schinkel; Stefan Schillberg
Journal:  Plant Cell Rep       Date:  2016-05-04       Impact factor: 4.570

2.  Patent Law and Genome Engineering: A Short Guide to a Rapidly Changing Landscape.

Authors:  Ross Cloney
Journal:  Mol Ther       Date:  2016-03       Impact factor: 11.454
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.